Weighted Gene Co-Expression Network Analysis and Support Vector Machine Learning in the Proteomic Profiling of Cerebrospinal Fluid from Extraventricular Drainage in Child Medulloblastoma.

artificial intelligence brain tumor cerebral spinal fluid extraventricular drainage mass spectrometry medulloblastoma proteomics

Journal

Metabolites
ISSN: 2218-1989
Titre abrégé: Metabolites
Pays: Switzerland
ID NLM: 101578790

Informations de publication

Date de publication:
05 Aug 2022
Historique:
received: 05 07 2022
revised: 25 07 2022
accepted: 02 08 2022
entrez: 25 8 2022
pubmed: 26 8 2022
medline: 26 8 2022
Statut: epublish

Résumé

Medulloblastoma (MB) is the most common pediatric malignant central nervous system tumor. Overall survival in MB depends on treatment tuning. There is aneed for biomarkers of residual disease and recurrence. We analyzed the proteome of waste cerebrospinal fluid (CSF) from extraventricular drainage (EVD) from six children bearing various subtypes of MB and six controls needing EVD insertion for unrelated causes. Samples included total CSF, microvesicles, exosomes, and proteins captured by combinatorial peptide ligand library (CPLL). Liquid chromatography-coupled tandem mass spectrometry proteomics identified 3560 proteins in CSF from control and MB patients, 2412 (67.7%) of which were overlapping, and 346 (9.7%) and 805 (22.6%) were exclusive. Multidimensional scaling analysis discriminated samples. The weighted gene co-expression network analysis (WGCNA) identified those modules functionally associated with the samples. A ranked core of 192 proteins allowed distinguishing between control and MB samples. Machine learning highlighted long-chain fatty acid transport protein 4 (SLC27A4) and laminin B-type (LMNB1) as proteins that maximized the discrimination between control and MB samples. Machine learning WGCNA and support vector machine learning were able to distinguish between MB versus non-tumor/hemorrhagic controls. The two potential protein biomarkers for the discrimination between control and MB may guide therapy and predict recurrences, improving the MB patients' quality of life.

Identifiants

pubmed: 36005596
pii: metabo12080724
doi: 10.3390/metabo12080724
pmc: PMC9412589
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

J Biol Chem. 2008 Jan 25;283(4):1773-7
pubmed: 18024425
Curr Oncol Rep. 2020 Jul 9;22(9):90
pubmed: 32643099
PLoS One. 2010 Jun 11;5(6):e10980
pubmed: 20552007
Cancer Cell Int. 2020 May 12;20:161
pubmed: 32425696
Biosci Rep. 2021 May 28;41(5):
pubmed: 33956061
Nucleic Acids Res. 2021 Jan 8;49(D1):D480-D489
pubmed: 33237286
CNS Oncol. 2017 Jan;6(1):71-82
pubmed: 28001090
Science. 1956 Feb 24;123(3191):309-14
pubmed: 13298683
Trends Cell Biol. 2017 Mar;27(3):172-188
pubmed: 27979573
Sci Rep. 2021 Jan 19;11(1):1818
pubmed: 33469081
Continuum (Minneap Minn). 2015 Apr;21(2 Neuro-oncology):373-96
pubmed: 25837902
Aging (Albany NY). 2019 Jul 15;11(13):4736-4756
pubmed: 31306099
Front Oncol. 2022 May 31;12:913740
pubmed: 35712471
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Proteomics. 2012 Feb;12(4-5):509-15
pubmed: 22246922
J Investig Med. 2022 Jun;70(5):1212-1218
pubmed: 35210328
ILAR J. 2002;43(4):207-13
pubmed: 12391396
Trends Biochem Sci. 2016 Mar;41(3):211-218
pubmed: 26778478
PLoS One. 2012;7(8):e42555
pubmed: 22880031
Acta Neuropathol. 2007 Aug;114(2):97-109
pubmed: 17618441
Nat Methods. 2014 Mar;11(3):319-24
pubmed: 24487582
PLoS One. 2012;7(7):e42064
pubmed: 22848702
J Neuropathol Exp Neurol. 2007 Jun;66(6):505-16
pubmed: 17549010
Electrophoresis. 2004 May;25(9):1327-33
pubmed: 15174055
Tumour Biol. 2016 May;37(5):6943-52
pubmed: 26662804
Int J Oncol. 2004 May;24(5):1279-88
pubmed: 15067352
Ann Transl Med. 2021 Aug;9(15):1237
pubmed: 34532374
Curr Treat Options Neurol. 2013 Oct;15(5):593-606
pubmed: 23979905
J Neurochem. 2011 May;117(4):735-46
pubmed: 21395585
Clin J Am Soc Nephrol. 2019 Jun 7;14(6):834-843
pubmed: 31018934
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
J Neurooncol. 2014 Jun;118(2):225-238
pubmed: 24771250
Clin Cancer Res. 2019 May 15;25(10):3115-3127
pubmed: 30679164
Oncogenesis. 2020 Feb 7;9(2):14
pubmed: 32034121
J Proteome Res. 2016 Dec 2;15(12):4412-4422
pubmed: 27801591
Acta Neuropathol. 2014 Feb;127(2):189-201
pubmed: 24264598
Neurosurg Rev. 2014 Jul;37(3):367-80; discussion 380
pubmed: 24781189
BMC Bioinformatics. 2012;13 Suppl 16:S12
pubmed: 23176165
Nutr Rev. 2006 May;64(5 Pt 2):S24-33; discussion S72-91
pubmed: 16770950
Proteomics. 2011 Mar;11(5):935-43
pubmed: 21271676
Cell. 2020 Feb 6;180(3):502-520.e19
pubmed: 31983537
Cerebrospinal Fluid Res. 2008 May 14;5:10
pubmed: 18479516
Front Cell Dev Biol. 2021 Mar 16;9:621618
pubmed: 33796525
Nutr Hosp. 2012 Nov-Dec;27(6):1860-5
pubmed: 23588432
Mol Cell Proteomics. 2018 Oct;17(10):1948-1964
pubmed: 30006486
Int J Mol Sci. 2020 Jul 03;21(13):
pubmed: 32635403
Sci Rep. 2015 Nov 09;5:16239
pubmed: 26548558
Int J Cancer. 2009 Dec 1;125(11):2624-30
pubmed: 19521960
J Proteome Res. 2010 Jan;9(1):70-8
pubmed: 19522540
Nucleic Acids Res. 2019 Jan 8;47(D1):D442-D450
pubmed: 30395289
J Proteomics. 2016 Mar 16;136:25-34
pubmed: 26850698
Cancer Cell. 2016 Dec 12;30(6):836-848
pubmed: 27960084
Acta Neuropathol Commun. 2018 Jun 7;6(1):48
pubmed: 29880060
Leukemia. 2015 Feb;29(2):297-303
pubmed: 24990611
FASEB J. 2016 Apr;30(4):1416-24
pubmed: 26655706
Oncotarget. 2017 Jul 11;8(28):46177-46190
pubmed: 28526811
Pharmacol Ther. 2020 Jun;210:107516
pubmed: 32105673
Int J Mol Sci. 2018 Nov 01;19(11):
pubmed: 30388870
Front Mol Biosci. 2022 Jan 04;8:796385
pubmed: 35059436
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
BMC Bioinformatics. 2008 Dec 29;9:559
pubmed: 19114008
Neuro Oncol. 2021 Apr 12;23(4):586-598
pubmed: 33175161
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Anticancer Res. 2021 Apr;41(4):1715-1726
pubmed: 33813375
Front Cell Dev Biol. 2020 May 27;8:275
pubmed: 32528946
Genome Biol. 2011;12(5):222
pubmed: 21639948
Cell Mol Biol Lett. 2013 Dec;18(4):595-611
pubmed: 24293108
Brain Pathol. 2020 May;30(3):664-678
pubmed: 32239782
Proteomics Clin Appl. 2018 May;12(3):e1700082
pubmed: 29148239
Metab Eng. 2017 Sep;43(Pt B):156-172
pubmed: 28087332
Neuro Oncol. 2012 May;14(5):547-60
pubmed: 22492959
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Sci Rep. 2021 Oct 21;11(1):20807
pubmed: 34675284
J Mol Biol. 2016 Feb 22;428(4):688-692
pubmed: 26434508

Auteurs

Maurizio Bruschi (M)

Laboratory of Molecular Nephrology, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy.

Xhuliana Kajana (X)

Laboratory of Molecular Nephrology, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy.

Andrea Petretto (A)

Core Facilities-Clinical Proteomics and Metabolomics, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy.

Martina Bartolucci (M)

Core Facilities-Clinical Proteomics and Metabolomics, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy.

Marco Pavanello (M)

Department of Neurosurgery, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy.

Gian Marco Ghiggeri (GM)

Division of Nephrology, Dialysis, Transplantation, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy.

Isabella Panfoli (I)

Dipartimento di Farmacia (DIFAR), Università di Genova, 16147 Genoa, Italy.

Giovanni Candiano (G)

Laboratory of Molecular Nephrology, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy.

Classifications MeSH